Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.62 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.57 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002135 | 1.00 | MEN1 (0.62) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL3515213 | 0.98 | MEN1 (0.63) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL3516120 | 0.94 | MEN1 (0.57) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL6468921 | 0.89 | MEN1 (0.60) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002137 | 0.87 | MEN1 (0.49) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002128 | 0.84 | MEN1 (0.55) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL14089180 | 0.84 | MEN1 (0.52) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002131 | 0.83 | MEN1 (0.57) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002138 | 0.79 | PLA2G2A (0.54) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002140 | 0.79 | PLA2G2A (0.54) | MEN1KMT2APAK1PLA2G2APLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846974-B2 | Method of lowering blood glucose and method of treating diabetes and obesity | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-7846974-B2 | Method of lowering blood glucose and method of treating diabetes and obesity | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090111893-A1 | METHOD OF LOWERING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING DIABETES AND OBESITY | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111893-A1 | METHOD OF LOWERING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING DIABETES AND OBESITY | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111893-A1 | METHOD OF LOWERING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING BLOOD GLUCOSE AND METHOD OF PREVENTING OR TREATING DIABETES AND OBESITY | HBG1, GPR119, GCKR | MEN1 2556/4885KMT2A 1125/4885PAK1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.